NBTY acquisition closes
This article was originally published in The Tan Sheet
Executive Summary
The Carlyle Group's $4 billion purchase of NBTY wraps up Oct. 1 after receiving an affirmative vote from the supplement firm's shareholders Sept. 22. Ronkonkoma, N.Y.-based NBTY is delisting from the New York Stock Exchange and shareholders are entitled to $55 in cash for each share of common stock. When the acquisition was announced in July, some analysts expected NBTY to attract higher bids during its 35-day "go-shop" period, but none materialized (1"The Tan Sheet" July 19, 2010)
You may also be interested in...
Carlyle Group's $3.8B Bid For NBTY Could Face Competition
The Carlyle Group's planned acquisition of NBTY for $3.8 billion may not be the only private equity offer to surface for the dietary supplement giant
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.